Compare Abeona Therapeutics Inc (ABEO) vs VNET Group Inc (VNET) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs VNET Group Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while VNET Group Inc trades at $8.38 (market cap $2.19B). The key difference: VNET Group Inc is far larger — about 5.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | VNET | |
|---|---|---|
Market Cap | $373.32M | $2.19B |
Sector | Health | Technology |
52-Week High | $7.23 | $14.03 |
52-Week Low | $4.17 | $6.97 |
Enterprise Value | $228.22M | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VNET trades at $7.81, down 1.39% today, amid bearish technical signals and recent earnings misses. The stock shows negative profitability with a -21.63% net income margin and -43.21% ROE for 2025, though revenue reached $9.95B. Analyst sentiment remains positive with 62.5% buy ratings, pointing to a 54% upside target. Recent news highlights strategic AI investments and leadership changes, while a class action settlement adds legal overhang.
The outlook is mixed: strong revenue growth and AI demand offer upside, but persistent losses and high debt pose risks. Investors should weigh analyst optimism against fundamental weaknesses and legal uncertainties before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
